Harbour Investments’s Trevi Therapeutics TRVI Stock Holding History

Harbour Investments’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-250	Closed	–	–	3619
2021 Q3	$0	Buy	+250	New	+$443	﹤0.01%	3985

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Harbour Investments's TRVI Position: Q4 2021 in Review

Harbour Investments sold out of Trevi Therapeutics (TRVI) in Q4 2021, closing a stake of 250 shares.

Harbour Investments first reported a position in TRVI in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 17 funds tracked by Wall St. Rank hold TRVI as of Q4 2021.

Harbour Investments reported no remaining Trevi Therapeutics position as of Q4 2021 after selling out during the quarter.
Harbour Investments sold 250 Trevi Therapeutics shares in Q4 2021.
Harbour Investments first reported a position in Trevi Therapeutics in Q3 2021 and held it in 1 quarter.
Harbour Investments's Trevi Therapeutics position peaked at $0 in Q3 2021.
17 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q4 2021.

Based on Harbour Investments's 13F filing for Q4 2021, filed 16 Feb 2022.